This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
Scientific Reports Open Access 06 September 2021
-
Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
BMC Medical Genetics Open Access 27 June 2019
-
Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children
Leukemia Open Access 29 June 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013; 123: 1544–1551.
Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of Calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013; 123: 1552–1555.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220–2228.
Tefferi A, Pardanani A . Genetics: CALR mutations and a new diagnostic algorithm for MPN. Nat Rev Clin Oncol 2014; 11: 125–126.
Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; e-pub ahead of print 5 February 2014; doi:10.1038/leu.2014.57.
Guglielmelli P, Nangalia J, Green AR, Vannucchi AM . CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. Am J Hematol 2014; 89: 453–456.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; e-pub ahead of print 9 January 2014; doi:10.1038/leu.2014.3.
Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 2014; e-pub ahead of print 26 February 2014; doi:10.1038/leu.2014.83.
Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.
Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121: 1604–1611.
Lasho TL, Elliott MA, Pardanani A, Tefferi A . CALR mutation studies in chronic neutrophilic leukemia. Am J Hematol 2014; 89: 450.
Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia 2014; e-pub ahead of print 12 March 2014; doi:10.1038/leu.2014.100.
Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128–5133.
Acknowledgements
This study was supported by 863 projects of Ministry of Science and Technology of China (2012AA02A211 and 2011ZX09302-007-04), National Natural Science Foundation of China (81270595), National Public Health Grand Research Foundation (No.201202017), Young Fund of Peking Union Medical College (2013) and Tianjin Municipal Science and Technology Commission (11JCZDJC18600 and 13JCZDJC31200).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Fu, R., Xuan, M., Zhou, Y. et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia 28, 1912–1914 (2014). https://doi.org/10.1038/leu.2014.138
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.138
This article is cited by
-
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
Clinical and Experimental Medicine (2023)
-
Cell-autonomous megakaryopoiesis associated with polyclonal hematopoiesis in triple-negative essential thrombocythemia
Scientific Reports (2021)
-
Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
BMC Medical Genetics (2019)
-
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era
Leukemia (2017)
-
Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis
Clinical and Translational Oncology (2017)